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Abstract
The clinicopathological and microbiological features of chromoblastomycosis caused by Fonsecaea pedrosoi or Fonsecaea monophora are
summarized. Four F. monophora and three F. pedrosoi strains were isolated from seven consecutive chromoblastomycosis patients and
identiﬁed by genetic analysis between 2004 and 2012 in a teaching hospital in southern China. Six strains were sensitive to voriconazole,
itraconazole and terbinaﬁne using E-test and Neo-Sensitabs. Six patients healed after oral itraconazole or terbinaﬁne, and one was lost to
follow up. Internal transcribed spacer sequence is sufﬁcient for species delimitation of Fonsecaea, and the Neo-Sensitabs test and E-test are
comparable in their susceptibility testing. Itraconazole and/or terbinaﬁne may be the preferred treatment for this chromoblastomycosis.
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Introduction
Chromoblastomycosis is characterized by polymorphic skin
lesions and muriform cells in the granulomatous and suppurative
tissue. Several dematiaceous fungi including the genera Fonsecaea,
Phialophora and Cladophialophora can lead to chromoblastomy-
cosis, of which Fonsecaea pedrosoi and Cladophialophora carrionii
are most frequent [1,2]. More than 500 cases of chromoblas-
tomycosis have been documented in mainland China since it was
ﬁrst reported in 1952, and the predominant pathogens are
C. carrionii in northern China and F. pedrosoi in southern China
[1]. The genus Fonsecaea comprises three species that can cause
human infections: F. pedrosoi, F. monophora and F. nubica;
F. pedrosoi and F. nubica are strictly associated with chromoblas-
tomycosis, whereas F. monophora is also involved in phaeohyph-
omycosis of brain and other organs [3]. Fonsecaea multimorphosa
was isolated from a feline cerebral abscess [4].
The skin lesions of chromoblastomycosis include nodular,
tumorous, verrucous, plaque and cicatricial types, and their
severity is divided into mild, moderate and severe forms [2].
Deﬁnite diagnosis of chromoblastomycosis is based on
clinicopathological data, especially recognition of the muri-
form cells in tissue and skin scrapings [2,5]. Although
morphological distinction of Fonsecaea species is difﬁcult,
PCR-based methods have been developed for their separation
[3,5]. Chromoblastomycosis is still a therapeutic challenge
because of the marked chronic lesions, dense dermal ﬁbrosis
and oedema, and there is no speciﬁed treatment of choice
[2,6].
Because the clinicopathological and microbiological data of
chromoblastomycosis caused by F. pedrosoi or F. monophora
are rarely compared, we aimed to delineate the clinical,
pathological and microbiological ﬁndings of seven consecutive
patients diagnosed by molecular identiﬁcation in our teaching
hospital between 2004 and 2012.
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Patients and Methods
Sample collection
Clinical, pathological and microbiological data of seven con-
secutive patients with culture-proven chromoblastomycosis
caused by Fonsecaea were retrospectively reviewed at our
department from 2004 to 2012. Skin biopsies were performed
in all cases, and the specimens were ﬁxed in 10% neutral
buffered formalin, embedded in parafﬁn, sectioned and stained
with haematoxylin & eosin (H&E), periodic acid-Schiff (PAS)
and argyrophilic nucleolar organizer region (AgNOR) stains.
Informed consents were obtained from all patients, and this
study was also approved by the ethics committee of our
hospital.
Mycological examination
Smears of skin scrapings and crushed tissues were observed in
10% potassium hydroxide, and cultured on Sabouraud dex-
trose agar to isolate the agents. The isolates were identiﬁed by
slide-culture microscopy.
DNA sequence analysis
Genomic DNA was extracted using a fungal DNA Mini Kit
(Omega Bio-Tek Inc., Norcross, GA, USA). The internal
transcribed spacer (ITS) and D1/D2 domain of rDNA were
ampliﬁed by ITS1 (5′-GTC GTA ACA AGG TTT CCG TAG
GTG-3′) and ITS4 (5′-TCC TCC GCT TAT TGA TAT GC-3′),
and NL1 (5′-GCA TAT CGG TAA GCG GAG GAA AAG-3′)
and NL4 (5′-GGT CCG TGT TTC AAG ACG G-3′),
respectively. Ampliﬁcation products underwent direct
sequencing, and the sequences were aligned with those in
GenBank by BLAST analysis.
Antifungal susceptibility testing
In vitro antifungal susceptibility testing of six Fonsecaea strains
was performed using Neo-Sensitabs (Rosco, Taastrup, Den-
mark) and E-test (AB bioMe´rieux, Askim, Sweden) following
the manufacturers’ instructions. Inoculum suspensions were
prepared by homogenizing moulds in 0.85% NaCl to achieve
0.5 McFarland turbidity. Modiﬁed Shadomy medium plates with
90-mm diameter (Guangzhou Detgerm Microbiology Tech-
nology Co., Ltd, Guangzhou, China) were used. Inoculum
suspension (a 0.5-mL sub-sample) was added to each plate, and
smeared evenly on the agar surface with a disposable sterile
swab. After drying at 35°C for 15 min, E-test strips or
Neo-Sensitabs tablets were gently placed on the lawn cultures.
The MICs and inhibition zone diameter were determined after
5 days of incubation at 27°C.
Results
The clinical data of four men and three women are summa-
rized in Table 1. There were six farmers and one worker, with
ages ranging from 45 to 84 years (mean of 63.3 years). All
patients were immunocompetent except for case 7 who had
untreated diabetes. The mean duration before presentation
was 49.3 months (range, 6–120 months). Only three cases had
a history of local injury caused by chicken or wood. All skin
lesions involved the extremities. Five patients had a solitary
plaque, one had three plaques, and one had a well-demarcated
ulcer. All but one had pain and itching. Of seven patients, ﬁve
achieved a complete resolution of skin lesions with itraconaz-
ole (0.2–0.4 g/day) for an average duration of 4.1 months
(range, 3–8 months) (Fig. 1a,b), and no relapse for a mean
follow-up of 43.4 months (range, 13–91 months); one under-
TABLE 1. Clinical and fungal results of seven cases of Fonsecaea-induced chromoblastomycosis
Case Date
Age
(years)/sex Clinical features/site
Duration
(m)
Treatment
regimen
Follow
up/response Pathogen
GenBank
accession number
1 2004.9 65/F 4.5 9 3.5 cm plaque/right ankle 12 ITZ (0.2 g/day) for
3 months
91 months/cure F. pedrosoi ITS: JN418758
D1/D2: JN418759
2 2006.2 51/M 5 9 3 cm plaque/right wrist 72 ITZ (0.2 g/day) for
8 months
69 months/cure F. monophora ITS: JQ906791
D1/D2: JQ906792
3a 2008.5 76/F 4 9 2.5 cm ulcer/left leg 9 No No F. pedrosoi ITS: JQ906789
D1/D2: JQ906790
4a 2010.5 63/F 4 9 4 cm plaque/left hand 6 ITZ (0.2 g/day) for
3.5 months
22 months/cure F. monophora ITS: JN418760
D1/D2: JN418761
5a 2010.5 59/M 5 9 4 cm plaque/right hand 6 ITZ (0.4 g/day) for
3 months
22 months/cure F. monophora ITS: JQ906793
D1/D2: JQ906794
6 2011.3 45/M 5 9 3 cm plaque/right wrist 120 ITZ (0.2 g/day) for
3 m
13 m/cure F. monophora ITS: JN418762
D1/D2: JN418763
7b 2012.2 84/M 10 9 5 cm, 4.5 9 2.5 cm
and
1 9 0.8 cm plaques/right
knee
120 ITZ (0.2 g/day) for
5 months, TBF
(0.25 g/day) for
1 months
In treatment F. pedrosoi ITS: JX134567
D1/D2: JX134568
F, female; M, male; ITZ, itraconazole; TBF, terbinaﬁne; ITS, internal transcribed spacer;
aHistory of local trauma.
bAssociated with diabetes.
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went a combined treatment with itraconazole (0.2 g/day) for
5 months and terbinaﬁne (0.25 g/day) for 1 month, and his
skin lesions healed substantially (Fig. 2a,b); one patient was lost
to follow up.
Direct smears revealed brown muriform cells and yellow-
ish-brown septate hyphae and acropetal chlamydospores
(Figs 1c and 2c). Fungal culture yielded dark olivaceous to
black fuzzy colonies at 27°C on Sabouraud dextrose agar after
2 weeks. Microscopic examination of slide culture showed
pale olivaceous septate hyphae, and loosely branched conid-
iophores bearing ellipsoidal conidia in short chains (Figs 1d and
2d). Histopathology of biopsy specimens in seven cases
demonstrated hyperkeratosis, pseudo-epitheliomatous hyper-
plasia and mixed granulomatous inﬂammation and neutrophil
microabscesses in the dermis. Staining with HE, PAS and
AgNOR revealed the muriform cells in granulomas, microab-
scesses or giant cells (Figs 1e–f and 2e–f).
The ITS and D1/D2 sequences of cases 1, 3 and 7 displayed
100% identity to a few strains of F. pedrosoi in GenBank except
the D1/D2 sequence of case 3 had one base difference. The
sequences of cases 2, 4, 5 and 6 showed 100% homology to
F. monophora (Table 1).
E-test results showed that the mean MICs of the six
Fonsecaea isolates were 0.024 (0.012–0.047) mg/L against
voriconazole, 0.125 mg/L against itraconazole, >32 mg/L
against amphotericin B and caspofungin, and >256 mg/L against
ﬂuconazole. The mean MICs were 0.025 (0.012–0.047) mg/L
against voriconazole for three F. monophora strains and 0.024
(0.012–0.047) mg/L for three F. pedrosoi strains. Neo-Sensitabs
results revealed that the six Fonsecaea isolates were sensitive
to voriconazole, itraconazole, ketoconazole and terbinaﬁne,
but resistant to ﬂuconazole and amphotericin B, except for
one strain of F. pedrosoi that was susceptible to amphotericin B
(Table 2).
Discussion
Fonsecaea species are saprobes in rotten wood, live plants and
soil [7]. Human Fonsecaea infections are presumably acquired
(a) (b)
(c) (d)
(e) (f)
FIG. 1. Clinicopathological and fungal
examination of Fonsecaea
monophora-induced
chromoblastomycosis. (a) Solitary
erythematous plaque on the dorsum of
left hand. (b) Complete healing with
hypopigmented scarring at 22-month
follow up. (c) Skin scrapings showing
muriform cells (10% KOH; original
magniﬁcation, 9400). (d) Microculture
on potato dextrose agar at 27°C on day
16 showing branched septate hyphae with
conidiophores bearing short conidial
chains (original magniﬁcation, 9400). (e)
Histopathology revealing three brown
acropetal septate chlamydospores
(haematoxylin & eosin; original
magniﬁcation, 91000). (f) Histopathology
revealing muriform cells (periodic
acid-Schiff; original magniﬁcation, 91000).
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after being pricked by contaminated thorns or wood splinters,
but the natural source, infection process and dispersal routes
are still unknown [8,9]. The environmental strains cannot
always be linked directly to clinical cases. The available
Fonsecaea strains can almost always be isolated from humans,
but rarely from the environment [8]. Fonsecaea monophora and
(a) (b)
(c) (d)
(e) (f)
FIG. 2. Clinicopathological and fungal
examination of Fonsecaea
pedrosoi-induced chromoblastomycosis.
(a) Three erythematous plaques with
dark brown crusts on the right knee. (b)
Nearly complete healing with
hypopigmented scarring after 5 months
of treatment. (c) Skin scrapings showing
brown muriform cells and
yellowish-brown septate hyphae and
acropetal chlamydospores (10% KOH;
original magniﬁcation, 9400). (d)
Microculture on potato dextrose agar at
27°C on day 12 showing branched septate
hyphae with conidiophores bearing short
conidial chains (original magniﬁcation,
9400). (e). Histopathology revealing
brown muriform cells (haematoxylin &
eosin; original magniﬁcation, 91000). (f).
Histopathology revealing dark brown
muriform cells (argyrophilic nucleolar
organizer region; original magniﬁcation,
91000).
TABLE 2. Minimal inhibitory concentration and inhibition zone diameter for six Fonsecaea isolates determined by E-test and
Neo-Sensitabs
Case Pathogen
MIC (mg/L)/IZD (mm)
VCZ ITZ AMB FLZ CAS KTZ TBF
1 F. pedrosoi 0.047/30(S) 0.125/35(S) >32/0(R) >256/0(R) >32/– –/28(S) –/54(S)
3 F. pedrosoi 0.012/52(S) 0.125/36(S) >32/0(R) >256/0(R) >32/– –/50(S) –/42(S)
4 F. monophora 0.047/43(S) 0.125/36(S) >32/0(R) >256/0(R) >32/– –/37(S) –/62(S)
5 F. monophora 0.016/44(S) 0.125/40(S) >32/0(R) >256/0(R) >32/– –/50(S) –/49(S)
6 F. monophora 0.012/55(S) 0.125/40(S) >32/0(R) >256/0(R) >32/– –/40(S) –/65(S)
7 F. pedrosoi 0.012/46(S) 0.125/45(S) >32/25(S) >256/0(R) >32/– –/40(S) –/48(S)
IZD, inhibition zone diameter; VCZ, voriconazole; ITZ, itraconazole; AMB, amphotericin B; FLZ, ﬂuconazole; CAS, caspofungin; KTZ, ketoconazole; TBF, terbinaﬁne; S,
susceptible; R, resistant; –, not done.
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unknown Fonsecaea species were isolated from an environ-
mental sampling performed in southern Brazil, but F. pedrosoi
was not [9]. Both F. pedrosoi and F. monophora are easily
misidentiﬁed in clinical practice because both have similar
morphological features. However, their pathogenic potential is
different. Fonsecaea pedrosoi may almost be a pathogen of
chromoblastomycosis, whereas F. monophora seems to be a
general opportunist [6]. In the seven subjects, all cases had
lesions on exposed areas, but only three had a history of
trauma and one had diabetes. Therefore, these infections
mainly involve otherwise healthy individuals and might
originate from minor traumatic implantation of environmental
fungi.
Diagnosis of chromoblastomycosis is dependent on direct
examination, fungal culture and histopathology, and the
existence of muriform cells in clinical samples is mandatory
[2]. In our study, sections stained with HE, PAS and AgNOR
from all patients revealed mixed granulomatous response,
microabscesses and muriform cells. Although multiple
PCR-based methods are suitable for their identiﬁcation, ITS
sequence analysis and phylogenetic study are most common
[3,5,7,8]. In line with the above reports, our study also
demonstrates that ITS sequence analysis is superior to the D1/
D2 sequence in species identiﬁcation of Fonsecaea.
The therapeutic outcomes of chromoblastomycosis are
variable according to infection site, lesion size, pathogen and
the host’s health status. Several treatment options yield
protracted disease, low cure rates and frequent relapse [10].
Severe lesions tend to respond slowly or even become
non-responsive to antifungal drugs [2]. In this study, ﬁve
patients with mild lesions had a satisfactory response to oral
itraconazole. In Case 7—an 84-year-old man with diabetes and
a 10-year history of multiple lesions—the skin lesions showed
an insigniﬁcant response to itraconazole at the start of therapy,
but disappeared almost completely after combined adminis-
tration of itraconazole and terbinaﬁne. The advanced age,
associated diabetes, long-standing course, and moderate
lesions could have accounted for the poor response to
itraconazole monotherapy.
Our susceptibility results showed that all strains were
sensitive to voriconazole and itraconazole by using E-test, and
to voriconazole, itraconazole, ketoconazole and terbinaﬁne by
Neo-Sensitabs. Clinical Fonsecaea isolates including F. pedrosoi,
F. monophora and F. nubica were susceptible to posaconazole,
itraconazole, isavuconazole and voriconazole, and the antifun-
gal activities of these drugs were not signiﬁcantly different [10].
Itraconazole and terbinaﬁne had a synergistic effect against the
F. monophora isolates [11]. The Neo-Sensitabs method has
been proven to be a quick and simple alternative to the E-test
assay for evaluating the susceptibility of ﬁlamentous fungi to
antifungals [12]. Our observation also suggests that the
Neo-Sensitabs test is comparable to E-test, and in vitro
susceptibility results of these strains are compatible with
clinical responses.
In conclusion, clinicopathological and mycological features
are alike in Fonsecaea-induced chromoblastomycosis, and ITS
sequence analysis is sufﬁcient for genetic delimitation of
Fonsecaea. Itraconazole and terbinaﬁne may be the anti-
fungals of choice in the treatment of this chromoblasto-
mycosis.
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